These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11744827)

  • 1. Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART).
    Morris MK; Katzenstein DA; Israelski D; Zolopa A; Hendry RM; Hanson CV
    J Acquir Immune Defic Syndr; 2001 Dec; 28(5):405-15. PubMed ID: 11744827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection.
    Kim JH; Mascola JR; Ratto-Kim S; VanCott TC; Loomis-Price L; Cox JH; Michael NL; Jagodzinski L; Hawkes C; Mayers D; Gilliam BL; Birx DC; Robb ML
    AIDS Res Hum Retroviruses; 2001 Jul; 17(11):1021-34. PubMed ID: 11485619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study.
    García F; Plana M; Arnedo M; Ortiz GM; Miró JM; Lopalco L; Lori F; Pumarola T; Gallart T; Gatell JM
    AIDS; 2003 Jan; 17(1):43-51. PubMed ID: 12478068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.
    Bongertz V; Ouverney EP; Fernandez SC; Grinsztejn B; Veloso V; Couto-Fernandez JC; Pilotto JH; Morgado MG
    Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):817-25. PubMed ID: 18060317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-receptor switch during HAART is independent of virological success.
    Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G
    J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
    Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
    Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mother to child transmission of HIV-1 in a Thai population: role of virus characteristics and maternal humoral immune response.
    Kittinunvorakoon C; Morris MK; Neeyapun K; Jetsawang B; Buehring GC; Hanson CV
    J Med Virol; 2009 May; 81(5):768-78. PubMed ID: 19319941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactions of Ugandan antisera with peptides encoded by V3 loop epitopes of human immunodeficiency virus type 1.
    Smith JD; Bruce CB; Featherstone AS; Downing RG; Biryahawaho B; Clegg JC; Carswell JW; Oram JD
    AIDS Res Hum Retroviruses; 1994 May; 10(5):577-83. PubMed ID: 7522494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy.
    Holtkamp N; Otteken A; Findhammer S; Miller V; Kurth R; Werner A
    J Infect Dis; 2000 Feb; 181(2):513-21. PubMed ID: 10669334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors associated with 10 years of continuous viral load suppression on HAART.
    Bello KJ; Mesner O; O'Bryan TA; Won SH; Lalani T; Ganesan A; Agan BK; Okulicz JF
    BMC Infect Dis; 2016 Jul; 16():351. PubMed ID: 27449671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy.
    Tan R; Westfall AO; Willig JH; Mugavero MJ; Saag MS; Kaslow RA; Kempf MC
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):553-8. PubMed ID: 18285713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
    Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
    J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates.
    Rubinstein A; Mizrachi Y; Pettoello-Mantovani M; Lenz J; Liu GQ; Rubinstein Y; Goldstein H; Yust I; Burke M; Vardinon N; Spirer Z; Cryz SJ
    J Acquir Immune Defic Syndr; 1999 Dec; 22(5):467-76. PubMed ID: 10961608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy.
    Brumme ZL; Dong WW; Yip B; Wynhoven B; Hoffman NG; Swanstrom R; Jensen MA; Mullins JI; Hogg RS; Montaner JS; Harrigan PR
    AIDS; 2004 Mar; 18(4):F1-9. PubMed ID: 15090786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
    Ortiz GM; Wellons M; Brancato J; Vo HT; Zinn RL; Clarkson DE; Van Loon K; Bonhoeffer S; Miralles GD; Montefiori D; Bartlett JA; Nixon DF
    Proc Natl Acad Sci U S A; 2001 Nov; 98(23):13288-93. PubMed ID: 11687611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.